Sydney Conover
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sydney Conover has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Gray
Center for Innovation to Implementation, VA Palo Alto Health Care System, Menlo Park, CA, United States
2 shared publications - Jenny Woo
Division of Vascular Surgery, Department of Surgery (J.W.), Stanford University, Palo Alto, CA
2 shared publications - Julia Mary Alber
California Polytechnic State University, San Luis Obispo, USA
2 shared publications - Julie Tsu-Yu Wu
Stanford Cancer Institute, Stanford University, Stanford, CA
2 shared publications - Shipra Arya
Stanford School of Medicine
2 shared publications - Catherine Freeland
Hepatitis B Foundation Doylestown Pennsylvania USA
1 shared publication
Latest Publications
- Open Access
- 5 February 2026
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 12 (1) , e80659
Navigating the Complexity of Lung Cancer Surveillance Practices: Qualitative Pilot Study on Provider Perspectives
Background: Surveillance is noted to be an important part of survivorship to detect recurrence and/or second primary lung cancer (SPLC) at a curable stage. However, current surveillance guidelines remain controversial, and the factors providers consider in clinical decision-making are neither well-defined nor consistently applied. Objective: In order to inform the qualitative protocol for a larger national study, this pilot study aimed to understand the factors that influence lung cancer surveillance and how providers view risk stratification as a potential tool to inform surveillance practices. Methods: Semistructured interviews were conducted between October 2023 and July 2024 with purposively sampled providers involved in treating and surveilling patients with lung cancer from the US-based Palo Alto Veterans Affairs Medical Center and Stanford Medicine and its affiliate clinics. Providers were recruited through both email outreach and in-person invitations. Interviews were transcribed by an external transcription service and analyzed through a qualitative inductive content analysis approach to identify themes. Results: In total, 11 physicians and 2 advanced practice providers (N=13) participated in interviews. The majority were from medical specialties (n=8, 61.5%), and the average number of years of practice as a provider was 9 years. A total of 3 themes were identified that describe the clinicians’ sentiments about current surveillance practices and how a risk stratification tool could be used in screening for recurrence and/or SPLC. Clinicians consider a variety of clinical and nonclinical factors (category 1: factors that influence clinical decision making) and highlighted limits of a risk stratification tool, including concerns about generalizability, accuracy, and validity (category 2: sentiments toward a hypothetical risk stratification tool). Finally, concerns were raised about how delivering risk stratification data might impact patient anxiety, misinterpretation, and adherence to surveillance plans (category 3: delivery of risk stratification data to patients). Conclusions: This qualitative analysis highlights the complexity of lung cancer surveillance decision-making and provider concerns about tool accuracy and delivery. While risk stratification tools may support surveillance decisions, their further development must address data quality, accuracy across diverse clinical and nonclinical risk factors, and effective patient-level data delivery. Doing so will facilitate the practical implementation of risk stratification tools to improve surveillance of SPLC and recurrence.
- 5 February 2026
- Published by JMIR Publications Inc. in JMIR Cancer
- Vol. 12 (1) , e80659
Open AccessNavigating the Complexity of Lung Cancer Surveillance Practices: Qualitative Pilot Study on Provider Perspectives
Background: Surveillance is noted to be an important part of survivorship to detect recurrence and/or second primary lung cancer (SPLC) at a curable stage. However, current surveillance guidelines remain controversial, and the factors providers consider in clinical decision-making are neither well-defined nor consistently applied. Objective: In order to inform the qualitative protocol for a larger national study, this pilot study aimed to understand the factors that influence lung cancer surveillance and how providers view risk stratification as a potential tool to inform surveillance practices. Methods: Semistructured interviews were conducted between October 2023 and July 2024 with purposively sampled providers involved in treating and surveilling patients with lung cancer from the US-based Palo Alto Veterans Affairs Medical Center and Stanford Medicine and its affiliate clinics. Providers were recruited through both email outreach and in-person invitations. Interviews were transcribed by an external transcription service and analyzed through a qualitative inductive content analysis approach to identify themes. Results: In total, 11 physicians and 2 advanced practice providers (N=13) participated in interviews. The majority were from medical specialties (n=8, 61.5%), and the average number of years of practice as a provider was 9 years. A total of 3 themes were identified that describe the clinicians’ sentiments about current surveillance practices and how a risk stratification tool could be used in screening for recurrence and/or SPLC. Clinicians consider a variety of clinical and nonclinical factors (category 1: factors that influence clinical decision making) and highlighted limits of a risk stratification tool, including concerns about generalizability, accuracy, and validity (category 2: sentiments toward a hypothetical risk stratification tool). Finally, concerns were raised about how delivering risk stratification data might impact patient anxiety, misinterpretation, and adherence to surveillance plans (category 3: delivery of risk stratification data to patients). Conclusions: This qualitative analysis highlights the complexity of lung cancer surveillance decision-making and provider concerns about tool accuracy and delivery. While risk stratification tools may support surveillance decisions, their further development must address data quality, accuracy across diverse clinical and nonclinical risk factors, and effective patient-level data delivery. Doing so will facilitate the practical implementation of risk stratification tools to improve surveillance of SPLC and recurrence.
- Open Access
- 14 July 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Navigating the Complexity of Lung Cancer Surveillance: Practices and Provider Perspectives (Preprint)
BACKGROUND Surveillance is noted to be an important part of survivorship to detect recurrence and/or second primary lung cancer (SPLC) at a curable stage. However, current surveillance guidelines remain controversial, and the factors providers consider in clinical decision-making are neither well-defined nor consistently applied. OBJECTIVE This study aims to understand factors that influence lung cancer surveillance and how providers view risk stratification as a potential tool to inform surveillance practices. METHODS Eleven physicians and two Advanced Practice Providers involved in treating and surveilling lung cancer patients from the Palo Alto Veterans Affairs medical center and Stanford medicine were interviewed between October 2023 and July 2024. Thematic categories were identified through a qualitative inductive content analysis approach. RESULTS We identified three thematic categories that describe clinicians' sentiments about current surveillance practices and how a risk stratification tool could be utilized in the screening for recurrence and/or SPLC. Clinicians consider a variety of clinical and non-clinical factors (Category 1: factors that influence clinical decision making), and highlighted limits of a risk stratification tool, including concerns about generalizability, accuracy, and validity (Category 2: sentiments toward a hypothetical risk stratification tool). Lastly, concerns were raised about how delivering risk stratification data might impact patient anxiety, misinterpretation, and adherence to surveillance plans (Category 3: delivery of risk stratification data to patients). CONCLUSIONS This qualitative analysis illustrates the complexity of lung cancer surveillance decision-making and provider concerns about tool accuracy and delivery, underscoring gaps to be addressed to facilitate development and adoption of risk stratification tools. Though risk stratification tools can serve as supplementary in lung cancer surveillance decision making, further development of such tools should address data quality, tool accuracy considering the wide array of clinical and non-clinical risks factors, and delivery of data to individual patients. Addressing these issues can inform the development and implementation of risk stratification tools in efforts towards efficient, universal and practical risk stratification of SPLC and/or recurrence in cancer survivors.
- 14 July 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessNavigating the Complexity of Lung Cancer Surveillance: Practices and Provider Perspectives (Preprint)
BACKGROUND Surveillance is noted to be an important part of survivorship to detect recurrence and/or second primary lung cancer (SPLC) at a curable stage. However, current surveillance guidelines remain controversial, and the factors providers consider in clinical decision-making are neither well-defined nor consistently applied. OBJECTIVE This study aims to understand factors that influence lung cancer surveillance and how providers view risk stratification as a potential tool to inform surveillance practices. METHODS Eleven physicians and two Advanced Practice Providers involved in treating and surveilling lung cancer patients from the Palo Alto Veterans Affairs medical center and Stanford medicine were interviewed between October 2023 and July 2024. Thematic categories were identified through a qualitative inductive content analysis approach. RESULTS We identified three thematic categories that describe clinicians' sentiments about current surveillance practices and how a risk stratification tool could be utilized in the screening for recurrence and/or SPLC. Clinicians consider a variety of clinical and non-clinical factors (Category 1: factors that influence clinical decision making), and highlighted limits of a risk stratification tool, including concerns about generalizability, accuracy, and validity (Category 2: sentiments toward a hypothetical risk stratification tool). Lastly, concerns were raised about how delivering risk stratification data might impact patient anxiety, misinterpretation, and adherence to surveillance plans (Category 3: delivery of risk stratification data to patients). CONCLUSIONS This qualitative analysis illustrates the complexity of lung cancer surveillance decision-making and provider concerns about tool accuracy and delivery, underscoring gaps to be addressed to facilitate development and adoption of risk stratification tools. Though risk stratification tools can serve as supplementary in lung cancer surveillance decision making, further development of such tools should address data quality, tool accuracy considering the wide array of clinical and non-clinical risks factors, and delivery of data to individual patients. Addressing these issues can inform the development and implementation of risk stratification tools in efforts towards efficient, universal and practical risk stratification of SPLC and/or recurrence in cancer survivors.
- Open Access
- 8 May 2022
- Published by Elsevier in PEC Innovation
- Vol. 1, 100049
Comparing lengths and inclusion of information in storytelling videos: Implications for Hepatitis B education
- 8 May 2022
- Published by Elsevier in PEC Innovation
- Vol. 1, 100049
Open AccessComparing lengths and inclusion of information in storytelling videos: Implications for Hepatitis B education
- 1 August 2021
- Published by Elsevier in Addictive Behaviors
- Vol. 119, 106939
Examining e-cigarette perspectives before and after the EVALI peak in cases
- 1 August 2021
- Published by Elsevier in Addictive Behaviors
- Vol. 119, 106939
Examining e-cigarette perspectives before and after the EVALI peak in cases